CORPUS CHRISTI, Texas, Oct. 27 /PRNewswire-FirstCall/ -- Consortium Service Management Group, Inc. (BULLETIN BOARD: CTUM) , announced today it has published a presentation for investors on the basics of its patented live- biological tissue-bonding/welding technology. The illustrated presentation is available for viewing on the company's investor relations website http://www.hawkassociates.com/csmg/primer.pdf .
Donald S. Robbins, CEO of CSMG, said, "The significant benefits of our platform technology are creating strong interest in the surgical community. Our patented techniques allow surgery with a minimum of blood loss, significantly faster healing, minimal scarring and less time in the operating room. This is of enormous benefit to both surgeons and patients. We created this educational piece for our shareholders to provide an update about the technology. Continuing requests have prompted us to post the information as a primer on our investor relations website."
CSMG owns the technology and exclusive world rights to the medical device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology. The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine at Kiev, Ukraine headed by Professor B.E. Paton.
About CSMG's Tissue-Bonding/Welding Technology
CSMG's patented tissue-bonding device bonds through radio-frequency fusion and reconnects living soft biological tissue (organs) without the use of foreign matter or conventional wound closing devices such as sutures, staples, sealant or glues. The technology leaves little or no scar visible to the naked eye after a few months. Unlike other tissue coagulation methods, the CSMG patented technology bonds and reconnects incised tissue, avoiding destruction of the tissue from charring, searing and necrosis by using a patented low-heat delivery method aimed at restoration of the normal functions of the live organs and tissue. United States and Australia patents have been issued with other U.S. and foreign patents pending.
Almost 3,000 successful human surgeries in clinical trials have been completed in Ukraine on various organs using a number of types of procedures. Today, surgeons at four Ukraine hospitals and clinics are using the tissue bonding/welding technology in clinical trials and performing between 80 and 100 new surgeries each month for open and laparoscopic surgical procedures and techniques. The procedures so far have involved the bonding and reconnecting of incised or separated human tissues in the following body areas -- nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, fallopian tube, ovary and testicles, dura-matter, lung -- while restoring the normal function of the body organ or tissue.
CSMG maintains offices in Corpus Christi, TX, Oklahoma City, OK and Kiev, Ukraine. The company website is http://www.ctum.com/ .
A profile for investors may be found at the website http://www.hawkassociates.com/csmg/profile.htm .
Additional information about CSMG can be found on the website http://www.ctum.com/ . An online investor kit containing CSMG press releases, SEC filings, current price Level II quotes, interactive Java, stock charts and other useful information for investors can be found at http://www.hawkassociates.com/ and http://www.hawkmicrocaps.com/ . Investors may contact Don Robbins or Gordon Allison, CSMG at (361) 887-7546, e-mail: publicrelations@ctum.com , or Frank Hawkins or Julie Marshall, Hawk Associates, at (305) 852-2383, e-mail: info@hawkassociates.com .
Consortium Service Management GroupCONTACT: Don Robbins or Gordon Allison, both of CSMG, +1-361-887-7546,or publicrelations@ctum.com ; or Frank Hawkins or Julie Marshall, both of HawkAssociates, at +1-305-852-2383, or info@hawkassociates.com , for CSMG